ARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas
http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20090914005400&newsLang=en